Breathe Well Live Well
Drug Discovery & Development |
Severe Asthma Drug Advances to Phase 3
Drug Discovery & Development The Phase 3 program will evaluate the safety and effectiveness of tralokinumab in reducing the rate of asthma exacerbations (AER) in adults and adolescents with severe, inadequately controlled asthma despite receiving inhaled corticosteroids plus … |
View full post on asthma – Google News
|
Dynavax Advances Agonist For Asthma Into The Clinic
Seeking Alpha Dynavax Technologies Corporation (DVAX) announced this morning it will advance its proprietary second-generation TLR-9 agonist for asthma into Phase 1 clinical studies. The work will be performed under the terms of a collaboration with AstraZeneca … Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma |
View full post on asthma – Google News
|
$3m for Vectura as asthma target advances
Cabume – Cambridge technology news Vectura has achieved a major milestone in its asthma drug target, triggering a $3m (£1.9m) payment from its unnamed US-based pharmaceutical partner and sending its share price up 5.9 per cent to 76.25p a share. That means Vectura is still on for a … Vectura updates on developmental products and milestones |
View full post on asthma – Google News
|
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute …
Sacramento Bee One of these agents, R343, an inhaled SYK inhibitor, will be entering a Phase 2 clinical study later this summer in mild to moderate asthmatic patients. The other, R256, an inhaled IL13 signaling/JAK inhibitor, is potentially useful in controlling … Rigel moving asthma drug into mid-stage trial |
View full post on asthma – Google News
|
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute …
MarketWatch (press release) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire via COMTEX/ — Rigel Pharmaceuticals, Inc., (NASDAQ:RIGL) is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma. |
View full post on asthma – Google News
 Financial Times |
AstraZeneca takes option on Prosidion diabetes assets; advances asthma drug
The Pharma Letter Separately, Dynavax Technologies (Nasdaq: DVAX) and AstraZeneca yesterday announced their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Investigational New Drug-enabling preclinical toxicology studies. … The Market Just Spanked My Stock! |
View full post on asthma – Google News
|
Advances with asthma and allergies
Daily Herald 24 issue of the journal Nature, which has several review articles on asthma, allergies, eczema, food allergies and related matters. First, some relevant facts: It is now well established that people raised on farms have only a third of the allergy … |
View full post on asthma – Google News
|
Advances in Aerosol Therapies for Asthma and More
EmpowHer (blog) The rescue inhaler for asthma is perhaps the most familiar form of aerosol therapy. When used properly, aerosol delivery of medication works … |
View full post on asthma – Google News